| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Biochemistry and Drug Metabolism, Hoffmann-LaRoche, Inc., Nutley, New Jersey 07110 [W. L., A. W. W., P. G. W., J. K., A. H. C.], and Section on Oxidation Mechanisms, Laboratory of Chemistry, National Institute of Arthritis, Metabolism and Digestive Diseases, NIH, Bethesda, Maryland 20014 [H. Y., D. M. J.]
Benzo(a)pyrene (BP) and several benzo-ring derivatives of BP were tested for carcinogenic activity in mice by topical application of each compound once every 2 weeks for 60 weeks. Chronic treatment of C57BL/6J mice with (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene (0.025 to 0.10 µmole/application) indicated that the dihydrodiol was slightly more active as a complete carcinogen than the parent hydrocarbon BP. 7,8-Dihydroxy-7,8,9,10-tetrahydrobenzo(a)pyrene, a compound related to (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene but which lacks the double bond at position 9,10, was inactive as a carcinogen on mouse skin. These results indicate the importance of the double bond at position 9,10 for the carcinogenic activity of (±)-trans-7,8-dihydroxy-7,8-dihydrobenzo(a)pyrene. Chronic treatment of mice with 0.4 µmole of the highly mutagenic (±)-7ß,8
-dihydroxy-9
,10
-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, (±)-7ß,8
-dihydroxy-9ß,10ß-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, or 9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene every 2 weeks for 60 weeks resulted in tumor incidences of 0, 8, and 4%, respectively, whereas BP at this dose caused a 100% tumor incidence. The high reactivity of the three epoxides may account for their inactivity or their weak carcinogenic activity on mouse skin.
1 To whom requests for reprints should be addressed.
Received 4/13/77. Accepted 6/21/77.
This article has been cited by other articles:
![]() |
M. C. Caino, J. L. Oliva, H. Jiang, T. M. Penning, and M. G. Kazanietz Benzo[a]pyrene-7,8-dihydrodiol Promotes Checkpoint Activation and G2/M Arrest in Human Bronchoalveolar Carcinoma H358 Cells Mol. Pharmacol., March 1, 2007; 71(3): 744 - 750. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Ding, J. Li, J. Chen, H. Chen, W. Ouyang, R. Zhang, C. Xue, D. Zhang, S. Amin, D. Desai, et al. Effects of Polycyclic Aromatic Hydrocarbons (PAHs) on Vascular Endothelial Growth Factor Induction through Phosphatidylinositol 3-Kinase/AP-1-dependent, HIF-1{alpha}-independent Pathway J. Biol. Chem., April 7, 2006; 281(14): 9093 - 9100. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Rubin Synergistic mechanisms in carcinogenesis by polycyclic aromatic hydrocarbons and by tobacco smoke: a bio-historical perspective with updates Carcinogenesis, December 1, 2001; 22(12): 1903 - 1930. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C. Özbal, P. L. Skipper, M. C. Yu, S. J. London, R. R. Dasari, and S. R. Tannenbaum Quantification of (7S,8R)-Dihydroxy-(9R,10S)-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene Adducts in Human Serum Albumin by Laser-induced Fluorescence: Implications for the in Vivo Metabolism of Benzo[a]pyrene Cancer Epidemiol. Biomarkers Prev., July 1, 2000; 9(7): 733 - 739. [Abstract] [Full Text] |
||||
![]() |
M Koreeda, P. Moore, P. Wislocki, W Levin, H Yagi, and D. Jerina Binding of benzo[a]pyrene 7,8-diol-9,10-epoxides to DNA, RNA, and protein of mouse skin occurs with high stereoselectivity Science, February 17, 1978; 199(4330): 778 - 781. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |